No End To US FDA Concerns About DEG And EG Testing, Or To OTC Firms Not Answering Its Calls

One of firms targeted in eight most recent warnings published since early September to OTC drug manufacturers, Zhao Qing Longda Biotechnology Co. in China, was dinged for both failing to respond to a request for records and for concerns about its production with DEG and EG.

• Source: Shutterstock

The latest warning letters from the US Food and Drug Administration show the agency still is finding manufacturing processes susceptible to diethylene glycol and ethylene glycol substitution and getting no response from some OTC firms to requests for records.

One of the firms targeted in the eight most recent warnings published since early September to OTC drug manufacturers, Zhao...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Compliance

More from Policy & Regulation